Could Big Biotech Earnings Be a Bust?
However, Oppenheimer's Hartaj Singh isn't so sure. He argues that expectations for large-cap biotechs are still too high, a situation that "should do little to dissipate the current negativity" around the stocks.
from Biotech News
0 Comments